Journal of Movement Disorders

Volume 14(1); January 2021

Review Articles

Perry Disease: Concept of a New Disease and Clinical Diagnostic Criteria: Yoshio Tsuboi, Takayasu Mishima, Shinsuke Fujioka; J Mov Disord. 2021;14(1):1-9. Published online September 21, 2020; DOI: https://doi.org/10.14802/jmd.20060

8,937 View
406 Download
14 Web of Science
14 Crossref

Perry disease is a hereditary neurodegenerative disease with autosomal dominant inheritance. It is characterized by parkinsonism, psychiatric symptoms, unexpected weight loss, central hypoventilation, and transactive-response DNA-binding protein of 43kD (TDP-43) aggregation in the brain. In 2009, Perry disease was found to be caused by dynactin I gene (DCTN1), which encodes dynactin subunit p150 on chromosome 2p, in patients with the disease. The dynactin complex is a motor protein that is associated with axonal transport. Presently, at least 8 mutations and 22 families have been reported; other than the “classic” syndrome, distinct phenotypes are recognized. The neuropathology of Perry disease reveals severe degeneration in the substantia nigra and TDP-43 inclusions in the basal ganglia and brain stem. How dysfunction of the dynactin molecule is related to TDP-43 pathology in Perry disease is important to elucidate the pathological mechanism and develop new treatment.

Citations

Citations to this article as recorded by

PSP-Richardson syndrome mimics: An overview and pragmatic approach
J. Necpál, M. Borsek, B. Jeleňová
Revue Neurologique.2024; 180(1-2): 12. CrossRef
Perry Disease: Bench to Bedside Circulation and a Team Approach
Takayasu Mishima, Junichi Yuasa-Kawada, Shinsuke Fujioka, Yoshio Tsuboi
Biomedicines.2024; 12(1): 113. CrossRef
Dysregulation of stress granule dynamics by DCTN1 deficiency exacerbates TDP-43 pathology in Drosophila models of ALS/FTD
Tetsuhiro Ueda, Toshihide Takeuchi, Nobuhiro Fujikake, Mari Suzuki, Eiko N. Minakawa, Morio Ueyama, Yuzo Fujino, Nobuyuki Kimura, Seiichi Nagano, Akio Yokoseki, Osamu Onodera, Hideki Mochizuki, Toshiki Mizuno, Keiji Wada, Yoshitaka Nagai
Acta Neuropathologica Communications.2024;[Epub] CrossRef
First family with Perry syndrome from Mexico
Leonardo Flores‑Lagunes, Luis Del Pozo‑Yauner, Karol Carrillo‑Sánchez, Carolina Molina‑Garay, Marco Jiménez‑Olivares, Joaquin Garcia‑Solorio, Ulises Rodríguez Corona, Guillermo Herrera, Edgar Ricardez‑Marcial, Carmen Alaez‑verson
Biomedical Reports.2024;[Epub] CrossRef
Extubation failure due to atypical parkinsonism with negligible motor and variable non-motor symptoms associated with a variant of DCTN1
Hidetada Yamada, Shuichiro Neshige, Hiroyuki Morino, Hirofumi Maruyama
Internal and Emergency Medicine.2023; 18(1): 329. CrossRef
Deficiency of Perry syndrome-associated p150Glued in midbrain dopaminergic neurons leads to progressive neurodegeneration and endoplasmic reticulum abnormalities
Jia Yu, Xuan Yang, Jiayin Zheng, Carmelo Sgobio, Lixin Sun, Huaibin Cai
npj Parkinson's Disease.2023;[Epub] CrossRef
Pathogenic Aspects and Therapeutic Avenues of Autophagy in Parkinson’s Disease
Rémi Kinet, Benjamin Dehay
Cells.2023; 12(4): 621. CrossRef
The genetic spectrum of a cohort of patients clinically diagnosed as Parkinson’s disease in mainland China
Yi-Min Sun, Xin-Yue Zhou, Xiao-Niu Liang, Jin-Ran Lin, Yi-Dan Xu, Chen Chen, Si-Di Wei, Qi-Si Chen, Feng-Tao Liu, Jue Zhao, Yi-Lin Tang, Bo Shen, Lin-Hua Gan, Boxun Lu, Zheng-Tong Ding, Yu An, Jian-Jun Wu, Jian Wang
npj Parkinson's Disease.2023;[Epub] CrossRef
Perry syndrome: Novel DCTN1 mutation in a large kindred and first observation of prodromal disease
Jarosław Dulski, Shunsuke Koga, Mercedes Prudencio, Philip W. Tipton, Shan Ali, Audrey J. Strongosky, Juliana H. Rose, Zoe A. Parrales, Judith A. Dunmore, Karen Jansen-West, Leonard Petrucelli, Dennis W. Dickson, Zbigniew K. Wszolek
Parkinsonism & Related Disorders.2023; 112: 105481. CrossRef
Perry Disease: Expanding the Genetic Basis
Jarosław Dulski, Shunsuke Koga, Paweł P. Liberski, Emilia J. Sitek, Ankur A. Butala, Jarosław Sławek, Dennis W. Dickson, Zbigniew K. Wszolek
Movement Disorders Clinical Practice.2023; 10(7): 1136. CrossRef
Monogenic Parkinson’s Disease: Genotype, Phenotype, Pathophysiology, and Genetic Testing
Fangzhi Jia, Avi Fellner, Kishore Raj Kumar
Genes.2022; 13(3): 471. CrossRef
Perry disease in an Argentine family due to the DCTN1 p.G67D variant
Emanuel Silva, Tatiana Itzcovich, Matías Niikado, Alejandro Caride, Elmer Fernández, Juan Carlos Vázquez, Leonardo Romorini, Mariela Marazita, Gustavo Sevlever, Horacio Martinetto, Ezequiel I. Surace
Parkinsonism & Related Disorders.2022; 97: 63. CrossRef
Clinical, pathological and genetic characteristics of Perry disease—new cases and literature review
Jarosław Dulski, Catalina Cerquera‐Cleves, Lukasz Milanowski, Alexa Kidd, Emilia J. Sitek, Audrey Strongosky, Ana María Vanegas Monroy, Dennis W. Dickson, Owen A. Ross, Jolanta Pentela‐Nowicka, Jarosław Sławek, Zbigniew K. Wszolek
European Journal of Neurology.2021; 28(12): 4010. CrossRef
Behavioral profile in a Dctn1G71A knock-in mouse model of Perry disease
Manami Deshimaru, Takayasu Mishima, Takuya Watanabe, Kaori Kubota, Mana Hosoi, Mariko Kinoshita-Kawada, Junichi Yuasa-Kawada, Maiko Ikeda, Masayoshi Mori, Yusuke Murata, Takaya Abe, Munechika Enjoji, Hiroshi Kiyonari, Shohta Kodama, Shinsuke Fujioka, Kats
Neuroscience Letters.2021; 764: 136234. CrossRef

Immune-Mediated Cerebellar Ataxias: Clinical Diagnosis and Treatment Based on Immunological and Physiological Mechanisms: Hiroshi Mitoma, Mario Manto, Marios Hadjivassiliou; J Mov Disord. 2021;14(1):10-28. Published online January 12, 2021; DOI: https://doi.org/10.14802/jmd.20040

23,698 View
783 Download
29 Web of Science
35 Crossref

Abstract PDF

Since the first description of immune-mediated cerebellar ataxias (IMCAs) by Charcot in 1868, several milestones have been reached in our understanding of this group of neurological disorders. IMCAs have diverse etiologies, such as gluten ataxia, postinfectious cerebellitis, paraneoplastic cerebellar degeneration, opsoclonus myoclonus syndrome, anti-GAD ataxia, and primary autoimmune cerebellar ataxia. The cerebellum, a vulnerable autoimmune target of the nervous system, has remarkable capacities (collectively known as the cerebellar reserve, closely linked to plasticity) to compensate and restore function following various pathological insults. Therefore, good prognosis is expected when immune-mediated therapeutic interventions are delivered during early stages when the cerebellar reserve can be preserved. However, some types of IMCAs show poor responses to immunotherapies, even if such therapies are introduced at an early stage. Thus, further research is needed to enhance our understanding of the autoimmune mechanisms underlying IMCAs, as such research could potentially lead to the development of more effective immunotherapies. We underscore the need to pursue the identification of robust biomarkers.

Citations

Citations to this article as recorded by

Different Purkinje cell pathologies cause specific patterns of progressive gait ataxia in mice
Dick Jaarsma, Maria B. Birkisdóttir, Randy van Vossen, Demi W.G.D. Oomen, Oussama Akhiyat, Wilbert P. Vermeij, Sebastiaan K.E. Koekkoek, Chris I. De Zeeuw, Laurens W.J. Bosman
Neurobiology of Disease.2024; 192: 106422. CrossRef
Paraneoplastic Cerebellar Degeneration Associated with Breast Cancer: A Case Report and a Narrative Review
Rosario Luca Norrito, Maria Grazia Puleo, Chiara Pintus, Maria Grazia Basso, Giuliana Rizzo, Tiziana Di Chiara, Domenico Di Raimondo, Gaspare Parrinello, Antonino Tuttolomondo
Brain Sciences.2024; 14(2): 176. CrossRef
Immune‐mediated spastic ataxia masquerading as clinically probable multisystem atrophy in an elderly woman
Rithvik Ramesh, Anuhya Chadalawada, Pedapati Radhakrishna, Lakshmi Narasimhan Ranganathan, Philo Hazeena, Sundar Shanmugam, Deepa Avadhani
Clinical and Experimental Neuroimmunology.2024; 15(3): 146. CrossRef
Paraneoplastic neurological syndromes: upgraded approaches to diagnosis
V. N. Grigoryeva, E. A. Ruina
Russian neurological journal.2024; 29(1): 4. CrossRef
Neuronal antibodies in nonparaneoplastic autoimmune cerebellar ataxias
Albert Saiz, Francesc Graus
Current Opinion in Neurology.2024; 37(3): 322. CrossRef
Paraneoplastic Cerebellar Ataxia: A Case Report and Literature Review
静刘
Advances in Clinical Medicine.2024; 14(03): 350. CrossRef
Autoantibodies related to ataxia and other central nervous system manifestations of gluten enteropathy
Tsvetelina Velikova, Georgi Vasilev, Russka Shumnalieva, Lyubomir Chervenkov, Dimitrina Georgieva Miteva, Milena Gulinac, Stamatios Priftis, Snezhina Lazova
World Journal of Clinical Cases.2024; 12(12): 2031. CrossRef
Clinical Presentation, Management, and Diagnostic Performance of 2021 Criteria for Paraneoplastic Neurologic Syndromes in Childhood
Ji Zhou, Mei Jin, Yan Su, Xiuwei Zhuo, Libing Fu, Xiaotun Ren, Changhong Ren, Anna Zhou, Jiuwei Li, Weihua Zhang
Neurology Neuroimmunology & Neuroinflammation.2024;[Epub] CrossRef
Recent advances in diagnosis of immune-mediated cerebellar ataxias: novel concepts and fundamental questions on autoimmune mechanisms
Hiroshi Mitoma, Mario Manto
Journal of Neurology.2024;[Epub] CrossRef
Onconeural antibody-associated cerebellar ataxia: An analysis
Rohan Mahale, Sandeep M, Anitha Mahadevan, Nitish Kamble, Vikram Holla, Pramod K. Pal, Ravi Yadav
Annals of Movement Disorders.2024; 7(2): 102. CrossRef
Autoimmunologische Kleinhirnerkrankungens
Niklas Vogel, Christian Hartmann, Sven Meuth, Nico Melzer
Nervenheilkunde.2023; 42(01/02): 73. CrossRef
Evaluation and management of acute high-grade immunotherapy-related neurotoxicity
Marcelo Sandoval, Adriana H. Wechsler, Zahra Alhajji, Jayne Viets-Upchurch, Patricia Brock, Demis N. Lipe, Aisha Al-breiki, Sai-Ching J. Yeung
Heliyon.2023; 9(3): e13725. CrossRef
Consensus Paper: Latent Autoimmune Cerebellar Ataxia (LACA)
Mario Manto, Marios Hadjivassiliou, José Fidel Baizabal-Carvallo, Christiane S Hampe, Jerome Honnorat, Bastien Joubert, Hiroshi Mitoma, Sergio Muñiz-Castrillo, Aasef G. Shaikh, Alberto Vogrig
The Cerebellum.2023; 23(2): 838. CrossRef
Proinflammatory activation of microglia in the cerebellum hyperexcites Purkinje cells to trigger ataxia
Shu-Tao Xie, Wen-Chu Fan, Xian-Sen Zhao, Xiao-Yang Ma, Ze-Lin Li, Yan-Ran Zhao, Fa Yang, Ying Shi, Hui Rong, Zhi-San Cui, Jun-Yi Chen, Hong-Zhao Li, Chao Yan, Qipeng Zhang, Jian-Jun Wang, Xiao-Yang Zhang, Xiao-Ping Gu, Zheng-Liang Ma, Jing-Ning Zhu
Pharmacological Research.2023; 191: 106773. CrossRef
Immune-related adverse events and immune checkpoint inhibitors: a focus on neurotoxicity and clinical management
Rosanna Ruggiero, Raffaella Di Napoli, Nunzia Balzano, Donatella Ruggiero, Consiglia Riccardi, Antonietta Anatriello, Andrea Cantone, Liberata Sportiello, Francesco Rossi, Annalisa Capuano
Expert Review of Clinical Pharmacology.2023; 16(5): 423. CrossRef
Immune-mediated ataxias: Guide to clinicians
Alex T. Meira, Marianna P.M. de Moraes, Matheus G. Ferreira, Gustavo L. Franklin, Flávio M. Rezende Filho, Hélio A.G. Teive, Orlando G.P. Barsottini, José Luiz Pedroso
Parkinsonism & Related Disorders.2023; 117: 105861. CrossRef
Gluten Ataxia: an Underdiagnosed Condition
Marios Hadjivassiliou, R. A. Grϋnewald
The Cerebellum.2022; 21(4): 620. CrossRef
Clinical Problem Solving: Decreased Level of Consciousness and Unexplained Hydrocephalus
Naomi Niznick, Ronda Lun, Daniel A. Lelli, Tadeu A. Fantaneanu
The Neurohospitalist.2022; 12(2): 312. CrossRef
Pharmacotherapy of cerebellar and vestibular disorders
João Lemos, Mario Manto
Current Opinion in Neurology.2022; 35(1): 118. CrossRef
Advances in the Pathogenesis of Auto-antibody-Induced Cerebellar Synaptopathies
Hiroshi Mitoma, Mario Manto
The Cerebellum.2022; 22(1): 129. CrossRef
A Breakdown of Immune Tolerance in the Cerebellum
Christiane S. Hampe, Hiroshi Mitoma
Brain Sciences.2022; 12(3): 328. CrossRef
Acute Cerebellar Inflammation and Related Ataxia: Mechanisms and Pathophysiology
Md. Sorwer Alam Parvez, Gen Ohtsuki
Brain Sciences.2022; 12(3): 367. CrossRef
A Case Report of Anti-PCA-2-Positive Autoimmune Cerebellitis
霞董
Advances in Clinical Medicine.2022; 12(04): 3272. CrossRef
Cell-Autonomous Processes That Impair Xenograft Survival into the Cerebellum
Lorenzo Magrassi, Giulia Nato, Domenico Delia, Annalisa Buffo
The Cerebellum.2022; 21(5): 821. CrossRef
Diagnosis and Clinical Features in Autoimmune-Mediated Movement Disorders
Pei-Chen Hsieh, Yih-Ru Wu
Journal of Movement Disorders.2022; 15(2): 95. CrossRef
Autoimmune cerebellar ataxia associated with anti-leucine-rich glioma-inactivated protein 1 antibodies: Two pediatric cases
Zhang Weihua, Ren Haitao, Deng Jie, Ren Changhong, Zhou Ji, Zhou Anna, Guan Hongzhi, Ren Xiaotun
Journal of Neuroimmunology.2022; 370: 577918. CrossRef
Anti-dipeptidyl-peptidase-like protein 6 encephalitis with pure cerebellar ataxia: a case report
Jing Lin, Min Zhu, Xiaocheng Mao, Zeqing Jin, Meihong Zhou, Daojun Hong
BMC Neurology.2022;[Epub] CrossRef
Central Positional Nystagmus
Ana Inês Martins, André Jorge, João Lemos
Current Treatment Options in Neurology.2022; 24(10): 453. CrossRef
Paraneoplastic Ataxia: Antibodies at the Forefront Have Become Routine Biomarkers
Lazaros C. Triarhou, Mario Manto
The Cerebellum.2022; 22(4): 534. CrossRef
Rare Etiologies in Immune-Mediated Cerebellar Ataxias: Diagnostic Challenges
Marios Hadjivassiliou, Mario Manto, Hiroshi Mitoma
Brain Sciences.2022; 12(9): 1165. CrossRef
Paraneoplastic Syndromes in Neuro-Ophthalmology
Simon J. Hickman
Annals of Indian Academy of Neurology.2022; 25(Suppl 2): S101. CrossRef
Immunotherapies for the Effective Treatment of Primary Autoimmune Cerebellar Ataxia: a Case Series
Jiao Li, Bo Deng, Wenli Song, Keru Li, Jingwen Ai, Xiaoni Liu, Haocheng Zhang, Yi Zhang, Ke Lin, Guofu Shao, Chunfeng Liu, Wenhong Zhang, Xiangjun Chen, Yanlin Zhang
The Cerebellum.2022; 22(6): 1216. CrossRef
Evaluation and Management of Acute High-Grade Immunotherapy-Related Neurotoxicity
Marcelo Sandoval, Adriana H. Wechsler, Zahra Alhajji, Jayne Viets-Upchurch, Patricia A. Brock, Demis N. Lipe, Aisha Al-Buraiki, Sai-Ching Jim Yeung
SSRN Electronic Journal .2022;[Epub] CrossRef
Stiff-Eye Syndrome—Anti-GAD Ataxia Presenting with Isolated Ophthalmoplegia: A Case Report
Abel Dantas Belém, Thaís de Maria Frota Vasconcelos, Rafael César dos Anjos de Paula, Francisco Bruno Santana da Costa, Pedro Gustavo Barros Rodrigues, Isabelle de Sousa Pereira, Paulo Roberto de Arruda Tavares, Gabriela Studart Galdino, Daniel Aguiar Dia
Brain Sciences.2021; 11(7): 932. CrossRef
Update on Paraneoplastic Cerebellar Degeneration
Philipp Alexander Loehrer, Lara Zieger, Ole J. Simon
Brain Sciences.2021; 11(11): 1414. CrossRef

Viewpoint

Impact and Challenges of the COVID-19 Pandemic on Patients Requiring Botulinum Toxin A Treatment: Azalea Tenerife Pajo, Adrian Isidoro Espiritu, Roland Dominic Go Jamora; J Mov Disord. 2021;14(1):29-33. Published online January 12, 2021; DOI: https://doi.org/10.14802/jmd.20088

8,896 View
180 Download
1 Web of Science
1 Crossref

PDF

Citations

Citations to this article as recorded by

COVID-19-related delays of botulinum toxin injections have a negative impact on the quality of life of patients with dystonia and spasticity: a single-center ambulatory care study
Yvonne Teuschl, Christian Bancher, Michael Brainin, Alexandra Dachenhausen, Karl Matz, Michaela M. Pinter
Journal of Neural Transmission.2022; 129(1): 49. CrossRef

Original Articles

The Queensland Parkinson’s Project: An Overview of 20 Years of Mortality from Parkinson’s Disease: Peter Cornelis Poortvliet, Alexander Gluch, Peter A. Silburn, George D. Mellick; J Mov Disord. 2021;14(1):34-41. Published online December 7, 2020; DOI: https://doi.org/10.14802/jmd.20034

11,107 View
230 Download
16 Web of Science
15 Crossref

Abstract PDF

Objective
The consensus is that life expectancy for individuals with Parkinson’s disease (PD) is reduced, but estimations vary. We aimed to provide an overview of 20 years of mortality and risk factor data from the Queensland Parkinson’s Project.
Methods
The analysis included 1,334 PD and 1,127 control participants. Preliminary analysis of baseline characteristics (sex, age at onset, family history, smoking status, pesticide exposure, depression and neurosurgery) was conducted, and Kaplan–Meier curves were generated for each potential risk factor. Standardized mortality ratios (SMRs) were calculated comparing this cohort to the general Australian population. Cox proportional hazards regression modeling was used to analyze potential predictors of mortality.
Results
In total, 625 (46.8%) PD and 237 (21.0%) control participants were deceased. Mean disease duration until death was 15.3 ± 7.84 years. Average ages at death were 78.0 ± 7.4 years and 80.4 ± 8.4 years for the deceased PD and control participants, respectively. Mortality was significantly increased for PD in general {SMR = 2.75 [95% confidence interval (CI): 2.53–2.96]; p = 0.001}. SMRs were slightly higher for women and those with an age of onset before 60 years. Multivariate analysis showed that deep brain stimulation (DBS) treatment was associated with lower mortality [hazard ratio (HR) = 0.76; 95% CI: 0.59–0.98], while occasional pesticide exposure increased mortality risk (HR = 1.48; 95% CI: 1.17–1.88). Family history of PD, smoking and depression were not independent predictors of mortality.
Conclusion
Mortality in PD is increased. Sex, age at onset and occasional pesticide exposure were independent determinants of increased mortality, while DBS treatment was associated with reduced mortality.

Citations

Citations to this article as recorded by

Update: Descriptive epidemiology of Parkinson disease
Nikolas Grotewold, Roger L. Albin
Parkinsonism & Related Disorders.2024; : 106000. CrossRef
Cost-effectiveness Analysis of COMT-inhibitors as Adjuvant Treatments to Levodopa in Patients with Advanced Parkinson's Disease
Nayoung Kwak, Myung-Jun Lee, Hye-Young Kang, Hankil Lee
Clinical Therapeutics.2024; 46(9): 670. CrossRef
Profiling people with Parkinson's disease at risk of cognitive decline: Insights from PPMI and ICICLE‐PD data
Dana Pourzinal, Rachael A. Lawson, Alison J. Yarnall, Caroline H. Williams‐Gray, Roger A. Barker, Jihyun Yang, Katie L. McMahon, John D. O'Sullivan, Gerard J. Byrne, Nadeeka N. Dissanayaka
Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring.2024;[Epub] CrossRef
Risk of aspiration pneumonia and hospital mortality in Parkinson disease: A systematic review and meta‐analysis
Wei Yu Chua, Jia Dong James Wang, Claire Kar Min Chan, Ling‐Ling Chan, Eng‐King Tan
European Journal of Neurology.2024;[Epub] CrossRef
Psychometric properties of Arabic-translated-related quality of life scales for people with parkinson disease: a scoping review
Chiraz Azaiez, Naser Chalghaf, Amayra Tannoubi, Noomen Guelmami, Medina Srem-Sai, Frank Quansah, John Elvis Hagan, Heifa Sneni, Ghada Boussayala, Imane Ghalmi, Mazin Inhaier Lami, Nicola Luigi Bragazzi, Stephane Mandigout, Choukri ben Ayed, Fairouz Azaiez
BMC Public Health.2024;[Epub] CrossRef
Indication for molecular testing by multiplex ligation‐dependent probe amplification in parkinsonism
E. Mutez, M. Swiderski, D. Devos, C. Moreau, G. Baille, A. Degardin, G. Ryckewaert, N. Carriere, A. Kreisler, C. Simonin, N. Rouaix, M. Tir, P. Krystkowiak, N. Ramdane, M. Génin, B. Sablonnière, L. Defebvre, V. Huin
European Journal of Neurology.2023; 30(6): 1667. CrossRef
Different pieces of the same puzzle: a multifaceted perspective on the complex biological basis of Parkinson’s disease
Amica C. Müller-Nedebock, Marieke C. J. Dekker, Matthew J. Farrer, Nobutaka Hattori, Shen-Yang Lim, George D. Mellick, Irena Rektorová, Mohamed Salama, Artur F. S. Schuh, A. Jon Stoessl, Carolyn M. Sue, Ai Huey Tan, Rene L. Vidal, Christine Klein, Soraya
npj Parkinson's Disease.2023;[Epub] CrossRef
Effects of omega-3 polyunsaturated fatty acids on the levels of pro- and anti-inflammatory cytokines and lipid profile in patients with Parkinson's disease
Sara Mohammadi, Mirmohsen Sharifi Bonab, Mahdyieh Hamed Behzad, Bahram Pourghassem Gargari
Nutrition Clinique et Métabolisme.2023; 37(3): 181. CrossRef
The elephant in the room: critical reflections on mortality rates among individuals with Parkinson’s disease
Lisanne J. Dommershuijsen, Sirwan K. L. Darweesh, Yoav Ben-Shlomo, Benzi M. Kluger, Bastiaan R. Bloem
npj Parkinson's Disease.2023;[Epub] CrossRef
Mortality of Parkinson’s disease in Italy from 1980 to 2015
Monica Ulivelli, Daiana Bezzini, Lucia Kundisova, Ilaria Grazi, Mario Alberto Battaglia, Nicola Nante, Simone Rossi
Neurological Sciences.2022; 43(6): 3603. CrossRef
A nationwide study of the incidence, prevalence and mortality of Parkinson’s disease in the Norwegian population
Brage Brakedal, Lilah Toker, Kristoffer Haugarvoll, Charalampos Tzoulis
npj Parkinson's Disease.2022;[Epub] CrossRef
Australian Parkinson’s Genetics Study (APGS): pilot (n=1532)
Svetlana Bivol, George D Mellick, Jacob Gratten, Richard Parker, Aoibhe Mulcahy, Philip E Mosley, Peter C Poortvliet, Adrian I Campos, Brittany L Mitchell, Luis M Garcia-Marin, Simone Cross, Mary Ferguson, Penelope A Lind, Danuta Z Loesch, Peter M Vissche
BMJ Open.2022; 12(2): e052032. CrossRef
Therapeutic targeting of mitophagy in Parkinson's disease
Shashank Masaldan, Sylvie Callegari, Grant Dewson
Biochemical Society Transactions.2022; 50(2): 783. CrossRef
Worldwide trends in mortality related to Parkinson's disease in the period of 1994–2019: Analysis of vital registration data from the WHO Mortality Database
Ioannis C. Lampropoulos, Foteini Malli, Olga Sinani, Konstantinos I. Gourgoulianis, Georgia Xiromerisiou
Frontiers in Neurology.2022;[Epub] CrossRef
Effects of physician visit frequency for Parkinson’s disease treatment on mortality, hospitalization, and costs: a retrospective cohort study
Takako Fujita, Akira Babazono, Sung-a Kim, Aziz Jamal, Yunfei Li
BMC Geriatrics.2021;[Epub] CrossRef

Health-Related Quality of Life for Parkinson’s Disease Patients and Their Caregivers: Michal Lubomski, Ryan L. Davis, Carolyn M. Sue; J Mov Disord. 2021;14(1):42-52. Published online January 12, 2021; DOI: https://doi.org/10.14802/jmd.20079

11,838 View
308 Download
28 Web of Science
26 Crossref

Abstract PDF

Objective
Motor and non-motor symptoms (NMS) negatively impact the health-related quality of life (HRQoL) for individuals with Parkinson’s disease (PD), as well as their caregivers. NMS can emerge decades prior to the manifestation of motor symptoms but often go unrecognized and therefore untreated. To guide clinical management, we surveyed differences and identified factors that influence HRQoL in a cohort of PD patients and family caregivers.
Methods
A total of 103 PD patients were compared with 81 caregivers. Outcome measures collected from validated questionnaires included generic and disease-specific HRQoL assessments, depression frequency and severity, constipation severity, upper and lower gastrointestinal symptoms, physical activity and motor symptom severity.
Results
PD patients reported significantly decreased physical and mental HRQoL compared to their caregivers (both p < 0.001). Unemployment, the need for social support services, rehabilitation use, REM sleep behavior disorder, impulse control disorders and features suggestive of increasing disease severity hallmarked by increasing PD duration, higher MDS UPDRS-III (Movement Disorder Society–Unified Parkinson’s Disease Rating Scale–Part III) scores, higher daily levodopa equivalence dose and motor fluctuations were consistent with a lower HRQoL in our PD cohort. Furthermore, decreased physical activity, chronic pain, depression, constipation and upper gastrointestinal dysfunction (particularly indigestion, excess fullness and bloating) suggested vulnerability to reduced HRQoL. Overall, PD patients perceived their health to decline by 12% more than their caregivers did over a 1-year period.
Conclusion
PD patients reported decreased HRQoL, with both motor symptoms and NMS negatively impacting HRQoL. Our findings support the routine clinical screening of HRQoL in PD patients to identify and address modifiable factors.

Citations

Citations to this article as recorded by

Risk factors and intervention of caregiver burden in Parkinson’s disease: a systematic review and meta-analysis
Yan Zhao, Wenxiang Wu, Jianjun Wu, Bin Shen, Yanpei Cao, Yafang Xu
Quality of Life Research.2024; 33(7): 1753. CrossRef
Health-related quality of life in Parkinson’s disease: systematic review and meta-analysis of EuroQol (EQ-5D) utility scores
Raghu Bhanupriya, Madhumitha Haridoss, Goda Suchitra Lakshmi, Bhavani Shankara Bagepally
Quality of Life Research.2024; 33(7): 1781. CrossRef
Factors associated with self-rated health in people with late-stage parkinson’s and cognitive impairment
Jennifer S. Pigott, Megan Armstrong, Nathan Davies, Daniel Davis, Bastiaan R. Bloem, Stefan Lorenzl, Wassilios G. Meissner, Per Odin, Joaquim J. Ferreira, Richard Dodel, Anette Schrag
Quality of Life Research.2024; 33(9): 2439. CrossRef
Understanding what aspects of Parkinson’s disease matter most to patients and families
Jennifer R. Mammen, Mirinda Tyo, Joyce Cadorette, Jamie L. Adams, Yuge Xiao, Diane Stephenson, Claire Bale
Scientific Reports.2024;[Epub] CrossRef
Impact of advanced Parkinson’s disease on caregivers: an international real-world study
Pablo Martinez-Martin, Matej Skorvanek, Tove Henriksen, Susanna Lindvall, Josefa Domingos, Ali Alobaidi, Prasanna L. Kandukuri, Vivek S. Chaudhari, Apeksha B. Patel, Juan Carlos Parra, James Pike, Angelo Antonini
Journal of Neurology.2023; 270(4): 2162. CrossRef
Perspectives of people with Parkinson's disease and family carers about disease management in community settings: A cross‐country qualitative study
M. Victoria Navarta‐Sánchez, Ana Palmar‐Santos, Azucena Pedraz‐Marcos, Claire Reidy, Dia Soilemezi, Anita Haahr, Dorthe Sørensen, Helle Rønn Smidt, Line Kildal Bragstad, Ellen Gabrielsen Hjelle, Silje Bjørnsen Haavaag, Mari Carmen Portillo
Journal of Clinical Nursing.2023; 32(15-16): 5201. CrossRef
Barriers to home exercise for patients with Parkinson’s disease: a qualitative study
Qiaohong Wang, Yiping Chen, Linbo Li, Chao Li, Li Li, Huili Cao, Hui Yang
BMJ Open.2023; 13(2): e061932. CrossRef
An update on pathogenesis and clinical scenario for Parkinson’s disease: diagnosis and treatment
Hussaini Adam, Subash C. B. Gopinath, M. K. Md Arshad, Tijjani Adam, N. A. Parmin, Irzaman Husein, Uda Hashim
3 Biotech.2023;[Epub] CrossRef
Gastrointestinal Dysfunction in Parkinson’s Disease: Neuro-Gastroenterology Perspectives on a Multifaceted Problem
Ai Huey Tan, Kee Huat Chuah, Yuan Ye Beh, Jie Ping Schee, Sanjiv Mahadeva, Shen-Yang Lim
Journal of Movement Disorders.2023; 16(2): 138. CrossRef
Abdominal pain in Parkinson’s disease
A.A. Pilipovich, O.V. Vorobyova, S.A. Makarov
Russian Journal of Pain.2023; 21(2): 12. CrossRef
The multifaceted impact of structured training program on persons with Parkinson disease and their adult caregiver: A protocol for a systematic review
Sharmila Gopala Krishna Pillai, Nor Azlin Mohd Nordin, Norlinah Mohamed Ibrahim
Medicine.2023; 102(28): e33966. CrossRef
Detecting Minor Symptoms of Parkinson’s Disease in the Wild Using Bi-LSTM with Attention Mechanism
Vasileios Skaramagkas, Iro Boura, Cleanthi Spanaki, Emilia Michou, Georgios Karamanis, Zinovia Kefalopoulou, Manolis Tsiknakis
Sensors.2023; 23(18): 7850. CrossRef
Lower gastrointestinal dysfunction in patients with Parkinson’s disease
A.A. Pilipovich, O.V. Vorob’eva, S.A. Makarov, A.V. Kuchuk
Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova.2023; 123(12): 42. CrossRef
The impact of device-assisted therapies on the gut microbiome in Parkinson’s disease
Michal Lubomski, Xiangnan Xu, Andrew J. Holmes, Jean Y. H. Yang, Carolyn M. Sue, Ryan L. Davis
Journal of Neurology.2022; 269(2): 780. CrossRef
Predictive Model of Quality of Life in Patients with Parkinson’s Disease
Eduardo Candel-Parra, María Pilar Córcoles-Jiménez, Victoria Delicado-Useros, Marta Carolina Ruiz-Grao, Antonio Hernández-Martínez, Milagros Molina-Alarcón
International Journal of Environmental Research and Public Health.2022; 19(2): 672. CrossRef
Die neue Parkinson-Schmerzklassifikation (PSK)
V. Mylius, S. Perez Lloret, C. S. Brook, M. T. Krüger, S. Hägele-Link, R. Gonzenbach, J. Kassubek, S. Bohlhalter, J. P. Lefaucheur, L. Timmermann, G. Kägi, F. Brugger, D. Ciampi de Andrade, J. C. Möller
Der Nervenarzt.2022; 93(10): 1019. CrossRef
Quantification Analysis of Sleep Based on Smartwatch Sensors for Parkinson’s Disease
Yi-Feng Ko, Pei-Hsin Kuo, Ching-Fu Wang, Yu-Jen Chen, Pei-Chi Chuang, Shih-Zhang Li, Bo-Wei Chen, Fu-Chi Yang, Yu-Chun Lo, Yi Yang, Shuan-Chu Vina Ro, Fu-Shan Jaw, Sheng-Huang Lin, You-Yin Chen
Biosensors.2022; 12(2): 74. CrossRef
Gastrointestinal Dysfunction Impact on Life Quality in a Cohort of Russian Patients with Parkinson’s Disease I-III H&Y Stage
A. A. Pilipovich, O. V. Vorob’eva, S. A. Makarov, N. N. Shindryaeva, Yu D. Vorob’eva, Seyed-Mohammad Fereshtehnejad
Parkinson's Disease.2022; 2022: 1. CrossRef
Nutritional Intake and Gut Microbiome Composition Predict Parkinson’s Disease
Michal Lubomski, Xiangnan Xu, Andrew J. Holmes, Samuel Muller, Jean Y. H. Yang, Ryan L. Davis, Carolyn M. Sue
Frontiers in Aging Neuroscience.2022;[Epub] CrossRef
The Gut Microbiome in Parkinson’s Disease: A Longitudinal Study of the Impacts on Disease Progression and the Use of Device-Assisted Therapies
Michal Lubomski, Xiangnan Xu, Andrew J. Holmes, Samuel Muller, Jean Y. H. Yang, Ryan L. Davis, Carolyn M. Sue
Frontiers in Aging Neuroscience.2022;[Epub] CrossRef
Characteristics and quality of life of substance users and their caregivers
Jadranka M. Maksimovic, Olivera B. Sbutega, Aleksandar D. Pavlovic, Hristina D. Vlajinac, Ivana I. Kavecan, Isidora S. Vujcic, Sandra B. Grujicic Sipetic
Medicine.2022; 101(31): e29699. CrossRef
Defining the unknowns for cell therapies in Parkinson's disease
Emma L. Lane, Mariah J. Lelos
Disease Models & Mechanisms.2022;[Epub] CrossRef
Increased Added Sugar Consumption Is Common in Parkinson's Disease
Natalie C. Palavra, Michal Lubomski, Victoria M. Flood, Ryan L. Davis, Carolyn M. Sue
Frontiers in Nutrition.2021;[Epub] CrossRef
Relationship Satisfaction in People with Parkinson’s Disease and Their Caregivers: A Cross-Sectional Observational Study
Johanne Heine, Hannah von Eichel, Selma Staege, Günter U. Höglinger, Florian Wegner, Martin Klietz
Brain Sciences.2021; 11(6): 822. CrossRef
Diagnosis and Management of Pain in Parkinson's Disease: A New Approach
Veit Mylius, Jens Carsten Möller, Stephan Bohlhalter, Daniel Ciampi de Andrade, Santiago Perez Lloret
Drugs & Aging.2021; 38(7): 559. CrossRef
Cognitive Influences in Parkinson's Disease Patients and Their Caregivers: Perspectives From an Australian Cohort
Michal Lubomski, Ryan L. Davis, Carolyn M. Sue
Frontiers in Neurology.2021;[Epub] CrossRef

Impact of Upper Eyelid Surgery on Symptom Severity and Frequency in Benign Essential Blepharospasm: Hannah Mary Timlin, Kailun Jiang, Daniel George Ezra; J Mov Disord. 2021;14(1):53-59. Published online January 12, 2021; DOI: https://doi.org/10.14802/jmd.20075

5,677 View
111 Download
2 Web of Science
2 Crossref

Abstract PDF

Objective
To assess the impact of periocular surgery, other than orbicularis stripping, on the severity and frequency of blepharospasm symptoms.
Methods
Consecutive patients with benign essential blepharospasm (BEB) who underwent eyelid/eyebrow surgery with the aim of improving symptoms were retrospectively reviewed over a 5-year period. Patients who had completed the Jankovic Rating Scale (JRS) and Blepharospasm Disability Index (BDI) pre- and at least 3 months postoperatively were included.
Results
Twenty-four patients were included. JRS scores significantly improved from 7.0 preoperatively to 4.1 postoperatively (p < 0.001), and BDI scores significantly improved from 18.4 preoperatively to 12.7 postoperatively (p < 0.001); the mean percentage improvements were 41% and 30%, respectively. Patients were followed for a median of 24 months postoperatively.
Conclusion
Periocular surgery significantly reduced BEB symptoms in the majority (83%) of patients by an average of 33% and may therefore be offered for suitable patients. An important minority (17%) of patients experienced symptom worsening.

Citations

Citations to this article as recorded by

The long-term response to botulinum toxin injections in patients with blepharospasm undergoing upper eyelid surgery
Assunta Trinchillo, Nunzia Cuomo, Francesco Habetswallner, Marcello Esposito
Parkinsonism & Related Disorders.2024; 119: 105958. CrossRef
Blepharospasm Secondary to Deep Brain Stimulation of the Subthalamic Nucleus in Parkinson Disease: Clinical Characteristics and Management Outcomes
Michelle A. Ting, Alexandra I. Manta, Emma Samia-Aly, Michelle Lai, Emanuel R. de Carvalho, Philip Buttery, Daniel G. Ezra
Journal of Neuro-Ophthalmology.2023;[Epub] CrossRef

Brief communication

Knowledge, Attitude, and Perceptions about Deep Brain Stimulation for Parkinson’s Disease: Observations from a Single Indian Center: Shweta Prasad, Amitabh Bhattacharya, Lulup Kumar Sahoo, Dhruv Batra, Nitish Kamble, Ravi Yadav, Dwarakanath Srinivas, Pramod Kumar Pal; J Mov Disord. 2021;14(1):60-64. Published online September 21, 2020; DOI: https://doi.org/10.14802/jmd.20066

6,058 View
145 Download
5 Web of Science
5 Crossref

Abstract PDF Supplementary Material

Objective
Willingness to undergo deep brain stimulation (DBS) among patients with Parkinson’s disease (PD) and their overall satisfaction with the procedure is highly dependent upon expectations, which are based on the core concepts of knowledge, attitude and perceptions. The present study aims to evaluate these factors in patients and caregivers with PD from a single tertiary care hospital in India.
Methods
A structured questionnaire designed to assess the knowledge, attitude and perceptions about DBS in PD was administered to 400 patients with PD and their caregivers.
Results
A very small proportion of patients and caregivers were aware of DBS. Even those who claimed to be aware of DBS were inadequately informed and had incorrect knowledge, which led to wrong attitudes and perceptions.
Conclusion
There are very significant knowledge gaps and misconceptions regarding DBS among patients with PD and caregivers. Adequate and appropriate education is necessary to clarify these misconceptions to avoid the development of unrealistic expectations and poor satisfaction.

Citations

Citations to this article as recorded by

Know DBS: patient perceptions and knowledge of deep brain stimulation in Parkinson’s disease
Meagen Salinas, Umar Yazdani, Austin Oblack, Bradley McDaniels, Nida Ahmed, Bilal Haque, Nader Pouratian, Shilpa Chitnis
Therapeutic Advances in Neurological Disorders.2024;[Epub] CrossRef
Assessment of Knowledge and Perception Regarding Deep Brain Stimulation Among Medical Students in Saudi Arabia
Sarah S Aldharman, Fadi A Munhish, Haila A Alabssi, Maryam A Alamer, Fay A Althunayyan, Majidah H Halawi, Shireen H Elfaham, Taghreed A Alsinani, Saud A Alnaaim
Cureus.2023;[Epub] CrossRef
Deep Brain Stimulation for Parkinson's Disease‐the Developing World's Perspective
Khushboo Patel, Divya Kalikavil Puthanveedu, Asish Vijayaraghavan, Krishnakumar Kesavapisharady, Gangadhara Sarma, Sankara P. Sarma, Syam Krishnan
Movement Disorders Clinical Practice.2023; 10(12): 1750. CrossRef
How Parkinson’s patients in the USA perceive deep brain stimulation in the 21st century: Results of a nationwide survey
Daniel Alfonso, Laura Y. Cabrera, Christos Sidiropoulos, Fei Wang, Harini Sarva
Journal of Clinical Neuroscience.2022; 95: 20. CrossRef
Caregiver Burden in Partners of Parkinsonian Patients with Deep Brain Stimulation
Eileen Gülke, Monika Pötter-Nerger
Brain Sciences.2022; 12(2): 238. CrossRef

Case Reports

Sialidosis Type I without a Cherry Red Spot— Is There a Genetic Basis?: Koti Neeraja, Vikram Venkappayya Holla, Shweta Prasad, Bharath Kumar Surisetti, Kempaiah Rakesh, Nitish Kamble, Ravi Yadav, Pramod Kumar Pal; J Mov Disord. 2021;14(1):65-69. Published online October 31, 2020; DOI: https://doi.org/10.14802/jmd.20083

5,416 View
152 Download
2 Web of Science
3 Crossref

Abstract PDF Supplementary Material

Sialidosis is an inborn error of metabolism due to a defect in the NEU1 gene and manifests as two phenotypes: mild type I and severe type II. The cherry red spot (CRS) is a characteristic feature in both types of sialidosis; reports of sialidosis without a CRS are rare. We report two cases of genetically confirmed sialidosis type I with a typical presentation of progressive cortical myoclonus and ataxia but without the CRS. A previously reported homozygous pathogenic variant p.Arg294Cys was detected in the first case, and a novel homozygous pathogenic variant p.Arg305Pro was detected in the second case. Additionally, we reviewed the literature describing cases with similar mutations to find a genetic basis for the absence of a CRS. Milder mutation of both alleles detected in both patients may be the reason for the absence of a CRS.

Citations

Citations to this article as recorded by

Unique clinical and electrophysiological features in the peripheral nerve system in patients with sialidosis – a case series study
Sung-Ju Hsueh, Chin-Hsien Lin, Ni-Chung Lee, Tung-Ming Chang, Sung-Pin Fan, Wan-De Huang, Yea-Huey Lin, Li-Kai Tsai, Yin-Hsiu Chien, Ming-Jen Lee, Wuh-Liang Hwu, Hsueh Wen Hsueh, Chih-Chao Yang
Orphanet Journal of Rare Diseases.2024;[Epub] CrossRef
Genotype-phenotype correlation and founder effect analysis in southeast Chinese patients with sialidosis type I
Yi-Chu Du, Ling-Han Ma, Quan-Fu Li, Yin Ma, Yi Dong, Zhi-Ying Wu
Orphanet Journal of Rare Diseases.2024;[Epub] CrossRef
A fuzzy rule based machine intelligence model for cherry red spot disease detection of human eyes in IoMT
Kalyan Kumar Jena, Sourav Kumar Bhoi, Debasis Mohapatra, Chittaranjan Mallick, Kshira Sagar Sahoo, Anand Nayyar
Wireless Networks.2023; 29(1): 247. CrossRef

New Nonsense Variant c.2983G>T; p.Glu995* in the CACNA1A Gene Causes Progressive Autosomal Dominant Ataxia: Yannic Saathoff, Saskia Biskup, Claudia Funke, Christian Roth; J Mov Disord. 2021;14(1):70-74. Published online October 31, 2020; DOI: https://doi.org/10.14802/jmd.20082

6,669 View
110 Download
2 Web of Science
2 Crossref

Abstract PDF

The genetic testing of hereditary ataxias includes screening for CAG-repeat expansions as well as pathogenic variants and nontranslated oligonucleotide expansion, which can cause spinocerebellar ataxia (SCA). Genotype-phenotype correlations of several SCA subtypes are difficult to establish, and the underlying mechanisms remain unclear. Here, we report a 58-year-old male patient who presented with severe generalized ataxia, horizontal gaze-evoked nystagmus, cognitive impairment and a positive family history of gait difficulties. Genetic panel diagnostics revealed a new nonsense pathogenic variant in the CACNA1A gene (c.2983G>T; p. Glu995*) that segregated with the phenotype in three clinically affected family members. This gene is related to SCA type 6 (SCA6), episodic ataxia type 2, familial hemiplegic migraine type 1, among others. When it is supported by the clinical findings and family history, additional DNA sequencing beyond fragment length analysis should be performed.

Citations

Citations to this article as recorded by

The genotype–phenotype correlations of the CACNA1A-related neurodevelopmental disorders: a small case series and literature reviews
Miriam Kessi, Baiyu Chen, Nan Pang, Lifen Yang, Jing Peng, Fang He, Fei Yin
Frontiers in Molecular Neuroscience.2023;[Epub] CrossRef
Next-Generation Sequencing Technologies and Neurogenetic Diseases
Hui Sun, Xiao-Rong Shen, Zi-Bing Fang, Zong-Zhi Jiang, Xiao-Jing Wei, Zi-Yi Wang, Xue-Fan Yu
Life.2021; 11(4): 361. CrossRef

Involuntary Movements Following Administration of Hydroxychloroquine for COVID-19 Pneumonia: Emmaline Zantua Fernando, Jeryl Ritzi Tan Yu, Salvador Miclat Abad Santos, Roland Dominic Go Jamora; J Mov Disord. 2021;14(1):75-77. Published online December 7, 2020; DOI: https://doi.org/10.14802/jmd.20091

5,982 View
124 Download
4 Web of Science
2 Crossref

Abstract PDF Supplementary Material

Hydroxychloroquine (HCQ) has been used as an investigational drug for patients with moderate to severe coronavirus disease 2019 (COVID-19). There have been concerns of potential harms from side effects of the drug. We present a case of a 38-year-old male who was started on HCQ for COVID-19 pneumonia. He was referred for evaluation of myoclonus of all extremities, which resolved after discontinuation of HCQ. The involuntary movements were first reported after the initiation of HCQ, persisted despite improvement in inflammatory and radiologic parameters and eventually resolved after HCQ discontinuation. This supports a possible causality related to adverse drug reactions from HCQ that have not been commonly reported.

Citations

Citations to this article as recorded by

Safety profile of COVID-19 drugs in a real clinical setting
Mei Nee Chiu, Maitry Bhardwaj, Sangeeta Pilkhwal Sah
European Journal of Clinical Pharmacology.2022; 78(5): 733. CrossRef
Eventos adversos no sistema nervoso central potencialmente relacionados aos medicamentos utilizados na COVID-19: revisão de escopo
Vinícius de Mello, Vinícius de Paula Pereira, João Paulo Vilela Rodrigues, Suelem Tavares da Silva Penteado, Leonardo Régis Leira Pereira, Fabiana Rossi Varallo
Revista Panamericana de Salud Pública.2022; 46: 1. CrossRef

Letters to the editor

COVID-19: Implications for Sudden Death in Parkinson’s Disease: Ana Claudia Fiorini, Marcelo Cunio Machado Fonseca, Carla Alessandra Scorza, Josef Finsterer, Antônio Márcio Rodrigues, Antônio-Carlos Guimarães de Almeida, Fulvio Alexandre Scorza; J Mov Disord. 2021;14(1):78-80. Published online August 31, 2020; DOI: https://doi.org/10.14802/jmd.20065

5,781 View
137 Download

PDF

A Rare Case of Green Gelatinous Mass Formation on a Deep Brain Stimulation Implantable Pulse Generator: Peter C. Poortvliet, George Mellick, Terry Coyne, Peter Silburn; J Mov Disord. 2021;14(1):81-83. Published online August 31, 2020; DOI: https://doi.org/10.14802/jmd.20050

5,827 View
67 Download
1 Web of Science
1 Crossref

PDF

Citations

Citations to this article as recorded by

Do Antibiotic-Impregnated Envelopes Prevent Deep Brain Stimulation Implantable Pulse Generator Infections? A Prospective Cohort Study
Michael Colditz, Tomas Heard, Peter Silburn, Terry Coyne
Stereotactic and Functional Neurosurgery.2024; 102(3): 137. CrossRef

Speech-Induced Task-Specific Cranio-Cervical Tardive Dystonia: An Unusual Phenomenology: Vikram Venkappayya Holla; J Mov Disord. 2021;14(1):84-85. Published online September 21, 2020; DOI: https://doi.org/10.14802/jmd.20067

4,914 View
81 Download
2 Web of Science
1 Crossref

PDF Supplementary Material

Citations

Citations to this article as recorded by

Treatment of tardive dystonia: A review
Paola Testini, Stewart A. Factor
Dystonia.2023;[Epub] CrossRef

The Case of a Patient with Pantothenate Kinase-Associated Neurodegeneration Presenting with a Prolonged History of Stuttering Speech and a Misdiagnosis of Parkinson’s Disease: Prashant A Natteru, Juebin Huang; J Mov Disord. 2021;14(1):86-88. Published online September 21, 2020; DOI: https://doi.org/10.14802/jmd.20062

6,028 View
103 Download
3 Web of Science
3 Crossref

PDF Supplementary Material

Citations

Citations to this article as recorded by

Perspective on investigation of neurodegenerative diseases with neurorobotics approaches
Silvia Tolu, Beck Strohmer, Omar Zahra
Neuromorphic Computing and Engineering .2023; 3(1): 013001. CrossRef
Pantothenate Kinase-Associated Neurodegeneration (PKAN) With Concomitant Blepharospasm: Unveiling a Clinical Enigma
Venkat Reddy, Keyur Saboo, Kavyanjali Reddy, Sunil Kumar, Sourya Acharya
Cureus.2023;[Epub] CrossRef
Enlarged Area of Mesencephalic Iron Deposits in Adults Who Stutter
Jan Liman, Alexander Wolff von Gudenberg, Mathias Baehr, Walter Paulus, Nicole E. Neef, Martin Sommer
Frontiers in Human Neuroscience.2021;[Epub] CrossRef

Generalized Chorea Due to Secondary Polycythemia Responding to Phlebotomy: Ajith Cherian, Naveen Kumar Paramasivan, Divya Kalikavil Puthanveedu, Syam Krishnan, Amitha Radhakrishnan Nair; J Mov Disord. 2021;14(1):89-91. Published online October 31, 2020; DOI: https://doi.org/10.14802/jmd.20081

4,806 View
94 Download
2 Web of Science
2 Crossref

PDF Supplementary Material

Citations

Citations to this article as recorded by

Monochorea after acute contralateral pontine infarction: A case report
Yun Su Hwang, Byoung-Soo Shin, Han Uk Ryu, Hyun Goo Kang
Medicine.2023; 102(3): e32660. CrossRef
Chorea in the Elderly: A Differential Diagnosis and Case Report of Late-Onset Huntington’s Disease in an Octogenarian
Alissa S. Higinbotham, Suzanne D. DeBrosse, Steven Gunzler
Journal of Huntington's Disease.2023; 12(4): 377. CrossRef

First
Prev
Page of 1
Next
Last

Previous issues